Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

176.51 +1.69 (+0.97%)
Streaming Delayed Price Updated: 11:47 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
News headline image
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen. 
Via Stocktwits
News headline image
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
From Biogen Inc.
Via GlobeNewswire
News headline image
What Does the Market Think About Biogen? ↗
 
Via Benzinga
News headline image
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash. 
Via Stocktwits
Topics Government
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
14 Analysts Have This To Say About Biogen ↗
 
Via Benzinga
News headline image
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio. 
Via Benzinga
News headline image
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space. 
Via Investor's Business Daily
Topics ETFs
News headline image
1 Profitable Stock with Exciting Potential and 2 to Avoid
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care. 
Via Benzinga
News headline image
Demystifying Biogen: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise 
From Biogen Inc.
Via GlobeNewswire
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above... 
Via StockStory
Topics World Trade
News headline image
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
News headline image
3 Cash-Producing Stocks Skating on Thin Ice
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
News headline image
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
4 Stocks to Buy for a Potential “Summer Panic” ↗
Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create... 
Via InvestorPlace
News headline image
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact ↗
Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment. 
Via Benzinga
News headline image
Biogen (NASDAQ:BIIB) Beats Q1 Sales Targets
Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was... 
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings
News headline image
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction ↗
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.